To: Courtney Willfore who wrote (89 ) 11/18/1997 8:41:00 AM From: r. peter Dale Respond to of 181
Courtney: My research concerns the role of compounds released by glia, with a focus on nitric oxide and SOD, during demyelination. So my focus is towards diseases such as MS although, as you suggest, some of the same glia-related factors play a role in neurodegenerative diseases as well. [A semantic note - neurodegenerative diseases describe processes where neurons degenerate and the loss of their myelin is a secondary consequence; demyelinating diseases involve loss of myelin where the death of the associated neuron is secondary. While the line between the two, on a biological basis, can be fuzzy at times, it's important for you to keep the language straight. If you come across statements, either here or even in the literature, where these terms are used interchangeably, treat the information with suspicion]. It has been a while since I've covered the PD literature; your father's condition may be just the catalyst for a refresher course. I'll attempt to answer your questions as my review proceeds. One thing you should seek out, to make your literature scanning less mundane, is to review the history of MPTP, a drug currently in wide use in animal models of PD (it induces PD in non-human primates, an invaluable tool for extrapolation to humans). The drug has a fascinating history: to pique your interest - it was 'discovered' in the early 1980's (?) when a California gentleman, in an attempt to illicitly manufacture methamphetamines, screwed up the synthesis. The pills hit the streets and within a short time many young adults were appearing in ERs frozen in position, just like end-stage PD. If you trace the complete history of MPTP/MPP+, you'll probably know all you would ever want to about this illness. Best wishes, Peter